ReviewFrontiers in oncology2025

Optimizing second-line endocrine-based treatment in HR positive HER2 negative metastatic breast cancer: a comprehensive expert statement from the Gulf Cooperation Council Region.

Ahmed Alshehri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.